[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556601":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":40,"centralContacts":45,"locations":51,"responsibleParty":162,"collaborators":166,"id":169,"slug":170,"hasResults":171,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":39,"eligibilityCriteria":175,"healthyVolunteers":171,"sex":176,"minAge":177,"maxAge":39,"enrollmentInfo":178,"targetDuration":39,"studyType":181,"phases":182,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":53,"whyStopped":39,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Ranolazine low dose","EXPERIMENTAL","Participants receive Ranolazine 500mg orally twice daily for 24 weeks.",[13],"Drug: Ranolazine",{"label":15,"type":10,"description":16,"interventionNames":17},"Ranolazine high dose","Participants receive Ranolazine 1000mg orally twice daily for 24 weeks.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Participants receive Ranolazine placebo orally twice daily for 24 weeks.",[23],"Drug: Placebo",[25,32,36],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Ranolazine","500mg twice daily",[9],[31],"Ranexa",{"type":26,"name":27,"description":33,"armGroupLabels":34,"otherNames":35},"1000 mg twice daily",[15],[31],{"type":26,"name":19,"description":37,"armGroupLabels":38,"otherNames":39},"Ranolazine placebo twice daily",[19],null,[41],{"name":42,"affiliation":43,"role":44},"Jeffrey Statland, MD","University of Kansas Medical Center","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":39,"email":50},"Katie Lillig, BS","CONTACT","913-945-9932","Kjennens2@kumc.edu",[52,74,91,107,126,143],{"facility":5,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","San Francisco","California","94143","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-122.41942,37.77493,{"lat":63,"lon":62},[66,70,72],{"name":67,"role":48,"phone":68,"phoneExt":39,"email":69},"Michael Han","415-353-7381","Michael.Han@ucsf.edu",{"name":39,"role":48,"phone":39,"phoneExt":39,"email":71},"Neuromuscular.Research@ucsf.edu",{"name":73,"role":44,"phone":39,"phoneExt":39,"email":39},"Swathy Chandrashekhar, MD",{"facility":75,"status":53,"city":76,"state":77,"zip":78,"country":57,"countryCode":58,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Mayo Clinic Florida","Jacksonville","Florida","32224",{"type":60,"coordinates":80},[81,82],-81.65565,30.33218,{"lat":82,"lon":81},[85,89],{"name":86,"role":48,"phone":87,"phoneExt":39,"email":88},"Huy B. Tran","904-953-4503","Tran.Huy1@mayo.edu",{"name":90,"role":44,"phone":39,"phoneExt":39,"email":39},"Bjorn E Oskarsson, MD",{"facility":43,"status":53,"city":92,"state":93,"zip":94,"country":57,"countryCode":58,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Fairway","Kansas","66205",{"type":60,"coordinates":96},[97,98],-94.6319,39.02223,{"lat":98,"lon":97},[101,105,106],{"name":102,"role":48,"phone":103,"phoneExt":39,"email":104},"Nick Staudenmier, BS","913-945-9922","nstaudenmier@kumc.edu",{"name":47,"role":48,"phone":49,"phoneExt":39,"email":50},{"name":42,"role":44,"phone":39,"phoneExt":39,"email":39},{"facility":108,"status":53,"city":109,"state":93,"zip":110,"country":57,"countryCode":58,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"University of Kansas Medical Center: Wichita","Wichita","67214",{"type":60,"coordinates":112},[113,114],-97.33754,37.69224,{"lat":114,"lon":113},[117,121,124],{"name":118,"role":48,"phone":119,"phoneExt":39,"email":120},"KUMC CTSU Wichita","316-293-1833","clinicaltrialunit@kumc.edu",{"name":122,"role":48,"phone":39,"phoneExt":39,"email":123},"Hannah Hancock","hhancock@kumc.edu",{"name":125,"role":44,"phone":39,"phoneExt":39,"email":39},"Matthew Byerly, MD",{"facility":127,"status":53,"city":128,"state":129,"zip":130,"country":57,"countryCode":58,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"University of Missouri Health Care","Columbia","Missouri","65212",{"type":60,"coordinates":132},[133,134],-92.33407,38.95171,{"lat":134,"lon":133},[137,141],{"name":138,"role":48,"phone":139,"phoneExt":39,"email":140},"Amanda Heider","573-884-6852","ahmc4@umsystem.edu",{"name":142,"role":44,"phone":39,"phoneExt":39,"email":39},"William D Arnold, MD",{"facility":144,"status":53,"city":145,"state":146,"zip":147,"country":57,"countryCode":58,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"The Ohio State University","Columbus","Ohio","43210",{"type":60,"coordinates":149},[150,151],-82.99879,39.96118,{"lat":151,"lon":150},[154,157,160],{"name":155,"role":48,"phone":39,"phoneExt":39,"email":156},"Atchayah Balakrishna","Atchayah.Balakrishna@osumc.edu",{"name":158,"role":48,"phone":39,"phoneExt":39,"email":159},"Kaneshia Hives","Kaneshia.Hives@osumc.edu",{"name":161,"role":44,"phone":39,"phoneExt":39,"email":39},"Sarah Heintzman, CNP",{"type":163,"investigatorFullName":164,"investigatorTitle":165,"investigatorAffiliation":5,"oldNameTitle":39,"oldOrganization":39},"SPONSOR_INVESTIGATOR","Swathy Chandrashekhar, MBBS","Principal Investigator",[167],{"name":168,"class":6},"ALS Association","100556601","phase-2-a-study-of-ranolazine-in-als-100556601",false,"NCT06527222","A Study of Ranolazine in ALS","Ranolazine in ALS: Safety, and Effect on Cramps, Function and Quality of Life.","Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with clinically definite, possible, probably, or lab-supported probable ALS per revised El Escorial criteria\n* Breathing assessment called forced vital capacity (FVC) greater than or equal to 50%.\n* Able to swallow pills at the start of the study and expected to for the length of the study.\n* If on ALS modifying medications must be on a stable dose at least 30 days.\n* Experiencing 4 or more cramps per week during a 2-week screening period.\n\nExclusion Criteria:\n\n* Disease duration \\\u003C 5 years\n* Tracheostomy invasive ventilation, or noninvasive ventilation of more than 12 hours\u002Fday\n* Pregnant or lactating, adults unable to consent, and prisoners\n* Taking ranolazine or investigational drug or has received an investigational drug within 30 days (or 5 half-lives for drugs, whichever is longer) prior to screening\n* Medically uncontrolled comorbidities (heart, liver, kidney disease)\n* Baseline QTc interval prolongation \\>450 ms for men\u002F \\>470 ms for women, history of long QT syndrome, or medications which prolong the QT interval\n* Participation in an experimental drug trial less than 30 days before screening\n* Patients have to be on a stable dosage of any medications used to treat muscle cramps for ≥30 days or have been off these medications ≥30 days prior to randomization.","ALL","18 Years",{"count":179,"type":180},72,"ESTIMATED","INTERVENTIONAL",[183],"PHASE2","The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.",[186],"Amyotrophic Lateral Sclerosis",[188,189,190,191],"ALS","Motor Neuron Disease","Lou Gehrig's Disease","Placebo-Controlled","2026-06-04",{"date":194,"type":195},"2026-06-08","ACTUAL",{"date":197,"type":195},"2025-04-29",{"date":199,"type":180},"2028-07",{"name":164,"class":6},6]